Testosterone and coronary artery disease

Cardiology in Review

Volumn 18, Issue 5, 2010, Pages 251-257

  Schwarcz, Monica D ^a   Frishman, William H ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; APOLIPOPROTEIN B; AROMATASE; BINDING PROTEIN; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ANDROGEN SYNTHESIS; ANDROGEN THERAPY; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HEART DISEASE; HEART MUSCLE; HEART MUSCLE PERFUSION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; ISCHEMIC HEART DISEASE; NONHUMAN; ORCHIECTOMY; PATHOGENESIS; REVIEW; RISK REDUCTION; TESTOSTERONE SYNTHESIS;

ANDROGENS; CORONARY ARTERY DISEASE; HUMANS; INCIDENCE; LIPIDS; LIPOPROTEINS; NEW YORK; PREVALENCE; RISK FACTORS; TESTOSTERONE;

EID: 77955787211     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181e84673     Document Type: Review

References (104)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N EnglJ Med. 1999;340:1801-1811.
2. Stamler J. The coronary drug project-findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol. 1977;82:52-75.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288: 321-333.
4. Hulley S, Grady D, Bush T, et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
5. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion no. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol. 2008;112:1189-1192.
6. Shabsigh R, Katz M, Yan G, et al. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol. 2005;96:67-72.
7. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29-39.
8. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21:890-894.
9. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87:3632-3639.
10. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (An-droGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
11. Zitzmann M. Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism. Asian J Androl. 2008;10:364-372.
12. Allan CA, Strauss BJ, Burger HG, et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139-146.
13. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-293.
14. Diano S, Horvath TL, Mor G, et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause. 1999;6:21-28.
15. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology. 2004; 145:1889-1897.
16. Kline LW, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signalling pathways. Steroids. 2008;73: 1174-1180.
17. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
18. Rosner W, Auchus RJ, Azziz R, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocrinol Metab. 2007;92:405-413.
19. Crawford ED, Barqawi AB, O'Donnell C, et al. The association of time of day and serum testosterone concentration in a large screening population. BJUInt. 2007;100:509-513.
20. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002; 87:589-598.
21. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86:724-731.
22. Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl. In press.
23. Frishman WH, Gomberg-Laitland M, Freeman R Hormones as cardiovascular drugs: estrogens, progestins, thyroxine, growth hormone, corticoste-roids and testosterone. In: Frishman WH, Sonnenblick EH, Sics DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:617-654.
24. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24:183-217.
25. Malkin CJ, Pugh PJ, Jones RD, et al. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003;178:373-380.
26. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature. 1993;366:215.
27. Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145:176-184.
28. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 1988; 78:539-545.
29. Cauley JA, Gutai JP, Kuller LH, et al. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987;60: 771-777.
30. Contoreggi CS, Blackman MR, Andres R, et al. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. JAndrol. 1990;11:460-470.
31. Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki heart study. Atherosclerosis. 1994;105:191-200.
32. Phillips GB, Yano K, Stemmermann GN. Serum sex hormone levels and myocardial infarction in the Honolulu heart program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol. 1988;41:1151-1156.
33. Yarnell JW, Beswick AD, Sweetnam PM, et al. Endogenous sex hormones and ischemic heart disease in men: the Caerphilly prospective study. Arte-rioscler Thromb. 1993;13:517-520.
34. Mikulec KH, Holloway L, Krasnow RE, et al. Relationship of endogenous sex hormones to coronary heart disease: a twin study. J Clin Endocrinol Metab. 2004;89:1240-1245.
35. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939-942.
36. Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660-1665.
37. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteron-emia with coronary artery disease in men. Arterioscler Thromb. 1994;14: 701-706.
38. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus [serial online]. Cochrane Database Syst Rev. 2005:CD003639.
39. van den Beld AW, Bots ML, Janssen JA, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25-31.
40. Demirbag R, Yilmaz R, Ulucay A, et al. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res. 2005;31:335-344.
41. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J ImpotRes. 2007;19:176-182.
42. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68-75.
43. Araujo AB, Kupelian V, Page ST, et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167:1252-1260.
44. Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534-543.
45. Nielsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab. 2007;92:2696-2705.
46. Osuna JA, Gomez-Perez R, Arata-Bellabarba G, et al. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl. 2006;52:355-361.
47. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451-1457.
48. Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone measurements performed by mass spectrometry methods. Steroids. 2009;74:498-503.
49. English KM, Jones RD, Jones TH, et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25: 455-458.
50. Alexandersen P, Haarbo J, Byrjalsen I, et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999;84:813-819.
51. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA. 2001;98:3589-3593.
52. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39:1217-1222.
53. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99: 1666-1670.
54. Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res. 2009;37:183-196.
55. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogo-nadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871-876.
56. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102: 1906-1911.
57. Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. In press.
58. Mathur A, Malkin C, Saeed B, et al. Long term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443-449.
59. Fogari R, Preti P, Zoppi A, et al. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res. 2005;28:625-630.
60. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207:318-327.
61. Jones RD, English KM, Jones TH, et al. Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clin Sci (Lond). 2004;107:149-158.
62. McGrath KC, McRobb LS, Heather AK. Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2008;4:11-21.
63. Charbit B, Christin-Maitre S, Demolis JL, et al. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol. 2009;103: 887-890.
64. Cavasin MA, Tao ZY, Yu AL, et al. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol. 2006;290:H2043-H2050.
65. Crisostomo PR, Wang M, Wairiuko GM, et al. Brief exposure to exogenous testosterone increases death signaling and adversely affects myocardial function after ischemia. Am J Physiol Regul Integr Comp Physiol. 2006; 290:R1168-R1174.
66. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829-1837.
67. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57-64.
68. Stergiopoulos K, Brennan JJ, Mathews R, et al. Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. Vasc Health Risk Manag. 2008;4:1475-1480.
69. Karila TA, Karjalainen JE, Mantysaari MJ, et al. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med. 2003;24:337-343.
70. De Piccoli B, Giada F, Benettin A, et al. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med. 1991;12:408-412.
71. Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997;88:218-220.
72. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91:2742-2747.
73. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866-873.
74. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997;82:682-685.
75. Auwerx JH, Marzetta CA, Hokanson JE, et al. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis. 1989;9:319-325.
76. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
77. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296:1051-1057.
78. Bagatell CJ, Bremner WJ. Androgen and progestogen effects on plasma lipids. Prog Cardiovasc Dis. 1995;38:255-271.
79. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261: 1165-1168.
80. Crist DM, Peake GT, Stackpole PJ. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol. 1986;13:513-518.
81. Taggart HM, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmeno-pausal osteoporosis. Metabolism. 1982;31:1147-1152.
82. Dai WS, Gutai JP, Kuller LH, et al. Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Car-diol. 1984;53:1259-1263.
83. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti area (InCHIANTI) study. Arch Intern Med. 2007;167:2249-2254.
84. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136-143.
85. Herbst KL, Amory JK, Brunzell JD, et al. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003;284:E1112-E1118.
86. Tan KC, Shiu SW, Pang RW, et al. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 1998;48:187-194.
87. Dobs AS, Bachorik PS, Arver S, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001;86:1026-1033.
88. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
89. Morley JE, Perry HM 3rd, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc. 1993;41:149-152.
90. Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003;58:618-625.
91. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testoster-one undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92:3844-3853.
92. Morgentaler A. Testosterone therapy in older men; the next big thing in medicine? Clin Geriatr. 2009;17:22-24.
93. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935-939.
94. Roddam AW, Allen NE, Appleby P, et al; Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
95. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
96. Worboys S, Kotsopoulos D, Teede H, et al. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab. 2001;86:158-161.
97. Miller KK. Androgen deficiency in women. J Clin Endocrinol Metab. 2001;86:2395-2401.
98. Phillips GB, Jing TY, Laragh JH. Serum sex hormone levels in postmeno-pausal women with hypertension. J Hum Hypertens. 1997;11:523-526.
99. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterio-scler Thromb Vasc Biol. 1997;17:695-701.
100. Buckler HM, McElhone K, Durrington PN, et al. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasono-graphic ovarian morphology in women. Clin Endocrinol (Oxf). 1998;49: 173-178.
101. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009; 94:2482-2488.
102. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-293.
103. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502-1510.
104. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (An-droGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.